I'm Anton Hellman.

I'm Justin Morganstern.

And this is the journal jam podcast.

EM cases is part of Shremie, the Schwartz-Riseman Emergency Medicine Institute.

That's the non-profit organization

dedicated to improving EM care through high-quality research and education. The opinions expressed on this podcast are intended for general information and educational purposes only and should not be used to diagnose treat or prevent any medical condition, nor should they be used as a substitute for medical advice from a qualified practicing physician. Unless stated otherwise, the opinions expressed by the hosts or guests are made in their individual capacity, not on behalf of the Institute nor medicine cases.

With the COVID-Omocrine wave, we're seeing a lot of COVID patients, but the vast majority are not so sick, and usually they can go home. Nonetheless, the numbers are so huge that even

though they don't seem to be getting as sick as alpha and delta patients, that denominator is so high

that the number of patients requiring hospitalization and or ICU admission is still pretty significant.

And most would agree that the key to preventing a generalized healthcare meltdown

is to prevent hospitalizations and ICU admissions.

We also, as usual, want to curb morbidity and mortality.

When I'm discharging a patient with COVID from the ED, I tell them to isolate.

I tell them to keep well hydrated and take acetymenophen or ibuprofen.

And almost universally, they ask me,

is that all you're going to offer me? Aren't you going to give me a prescription?

In this journal jam podcast, we're going to dig deep into the science of FDA-approved outpatient

medications for COVID with three critical appraisal masters.

Infectious disease specialist Andrew Morris, who you've almost certainly heard before on

EM cases, my EM colleague at North York General and Sremi researcher Rohit Mohindra.

Say hi, Hi, Rohit.

Hi, everyone.

...